Apolipoprotein B, Residual Cardiovascular Risk After Acute Coronary Syndrome, and Effects of Alirocumab

This analysis of the ODYSSEY OUTCOMES trial tested whether apolipoprotein B is a better guide to residual risk — and a better treatment target — than LDL cholesterol in patients after a heart attack.

The findings favored apoB decisively. Risk of recurrent events rose steadily with higher baseline apoB, and the PCSK9 inhibitor alirocumab reduced risk across all apoB levels, with the largest absolute gains in those starting highest. Most striking, the achieved apoB at four months predicted future events down to very low levels (≤35 mg/dL) — and in head-to-head modeling, achieved apoB remained predictive after adjusting for LDL or non-HDL cholesterol, while those measures lost their predictive power once apoB was accounted for.

This is strong trial-embedded evidence that apoB captures atherogenic risk that LDL misses, and that driving apoB very low yields benefit. It supports apoB as the more informative treatment target in high-risk patients.

We rate the evidence strong. As a pre-specified analysis of a large randomized trial it carries real weight, with the modest caveat that it is a secondary analysis rather than a trial designed around apoB targets.